XTL Biopharma Holds Shareholder Meeting
Ticker: XTLB · Form: 6-K · Filed: Jul 28, 2025 · CIK: 1023549
| Field | Detail |
|---|---|
| Company | Xtl Biopharmaceuticals Ltd (XTLB) |
| Form Type | 6-K |
| Filed Date | Jul 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance
TL;DR
XTL Biopharma held its shareholder meeting on July 21st, 2025, to vote on key company matters.
AI Summary
XTL Biopharmaceuticals Ltd. announced on June 13, 2025, that its Annual and Extraordinary General Meeting of Shareholders would be held on July 21, 2025, in Bnei Brak, Israel. The meeting was convened to discuss and vote on various corporate matters.
Why It Matters
This filing details the procedural aspects and outcomes of a shareholder meeting, which is crucial for corporate governance and decision-making.
Risk Assessment
Risk Level: low — The filing is a routine report of a shareholder meeting and does not contain significant new financial or operational information that would typically increase risk.
Key Players & Entities
- XTL Biopharmaceuticals Ltd. (company) — Registrant
- June 13, 2025 (date) — Announcement date of meeting
- July 21, 2025 (date) — Date of shareholder meeting
- Doron Tikotzky Kantor Gutman & Co (company) — Company's attorneys and meeting location
FAQ
When was the Annual and Extraordinary General Meeting of Shareholders announced?
The meeting was announced on June 13, 2025.
What was the date of the Annual and Extraordinary General Meeting of Shareholders?
The meeting was held on July 21, 2025.
Where was the shareholder meeting held?
The meeting was held at the offices of the Company's attorneys, Doron Tikotzky Kantor Gutman & Co, 7 Metsada St., B.S.R Tower 4, 33 Floor, Bnei Brak, Israel.
What is the company's principal executive office address?
The principal executive offices are located at 26 Ben-Gurion St., Ramat Gan, 5112001, Israel.
Does XTL Biopharmaceuticals file annual reports under Form 20-F or 40-F?
XTL Biopharmaceuticals files annual reports under Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 28, 2025 regarding XTL BIOPHARMACEUTICALS LTD (XTLB).